pharma · Multiple Myeloma · Ovarian Cancer
pharma&
pharmaand GmbH
pharmaand is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s
Company details
- Status
- Public
- HQ
- Vienna, AT
- Founded
- 2017
- Employees
- 210
- Programs
- 3
- Drugs
- 16
- Patents
- 0
Quick answer
pharmaand is a pharma organization headquartered in Wien, AT. Primary therapeutic focus areas include Multiple Myeloma, Ovarian Cancer. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 3 (2), phase 2 (1).
Company snapshot
pharmaand GmbH (pharma&) is a global, privately owned pharmaceutical company headquartered in Vienna, Austria. Our mission is preserving the availability and fostering the further development of essential medicines worldwide, to leave no patient behind. Since 2017, we have acquired the worldwide rights to more than 10 high-need specialty therapeutics, with an increasing focus on hematology and onc
- 3 active pipeline program(s) linked via ClinicalTrials.gov.
- 3 trial update(s) in the last 12 months.
Public regulatory, clinical, patent, and corporate records for pharma&. Not investment advice.
Catalysts
Upcoming readouts, regulatory dates, and congress activity.
- approval
Regeneron Pharma Stock Surges: Fresh Institutional Buying Insights
- approval
GSK and Alfasigma Licensing Agreement, Servier's $2.5B Acquisition
- approval
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect Program
- approval
Naldemedine Approved in China for Opioid-Induced Constipation: A New Option for Cancer Supportive Care
- deal
BMS-Hengrui $15B Deal: Strategic Implications for Pharma Executives
- trial_data
Newron Pharmaceuticals to Present at Upcoming Investor Conferences
- deal
Minghui and Qilu Pharmaceutical Unveil Promising MHB088C Data in mCRPC at ASCO 2026
- approval
Gilead Secures First Hepatitis D Drug Approval, Sparking Bay Area Competition
- approval
Elite Pharma Files FDA ANDA for $26B Generic Blood Thinner, Targeting Key Anticoagulant Market
- approval
MaaT Pharma Q1 2026 Update: Financials, Business Progress, and Strategic Outlook
- approval
Big Pharma's Shift to Smaller Deals Boosts Biotech Sector
- approval
Rusan Pharma Secures PMDA GMP Approval, Boosting Global Market Access
Recent coverage
Hillhurst Bio doses first subject in Phase 2a HBI-002 Parkinson's trial
Hillhurst Bio doses first subject in a Phase 2a clinical trial of HBI-002 for Parkinson's disease. The study is recruiting and is listed on ClinicalTrials.gov as a randomized, double-blind, placebo-controlled multiple-dose trial.
Alembic Wins Tentative FDA Nod for First Generic Larotrectinib Capsules
Alembic Pharmaceuticals received tentative FDA approval for generic larotrectinib capsules in 25 mg and 100 mg strengths. The move marks a key catalyst for Vitrakvi competition, with final launch timing still dependent on remaining patent or exclusivity issues.
Alnylam pipeline update: AMVUTTRA catalysts, outlook and profitability
Alnylam pipeline momentum is anchored by AMVUTTRA’s FDA-approved ATTR-CM and hATTR-PN uses, plus two active Phase 3 catalysts. The update focuses on what changed, what it means for investors, and what to watch next.
Tillomed Laboratories update: pipeline, melphalan and next catalysts
Tillomed Laboratories Ltd is owned by Emcure and operates across a broad portfolio spanning oncology, anti-infectives, women’s health, and more. This update focuses on the company’s melphalan link, competitive set, and what BD teams and investors should watch next.
Top assets
Lead pipeline drugs
- Marketed / approved
- Marketed / approved
- Marketed / approved
- Marketed / approved
Active clinical programs
- Phase 3
- Phase 3
- Phase 2
Congress & presentations
Momentum
Proprietary activity score for pharma&.
2 active signals
Signal breakdown
- Clinical trials
- Nova articles
- Patents filed
- FDA actions
- SEC filings
- Conference presentations
- Pipeline advances
Competitor landscape
Therapeutic-area overlap peers from registry and pipeline signals.
- Peer + 0 momentum
Recent activity
Latest pipeline, patent, and corporate events for pharma&.
- Clinical update
- Clinical update
- Clinical update
Quick answers
Common questions about this sponsor — for analysts and search.
-
What is pharma&?
-
Is pharma& publicly traded?
-
What drugs does pharma& develop or market?
-
What are the latest developments for pharma&?
-
What therapeutic areas does pharma& focus on?
Therapeutic focus
Therapeutic area distribution
Pipeline concentration by therapeutic area from linked clinical programs.